AstraZeneca’s Japan Sales Surge 28% in H1 on Oncology Growth

August 6, 2019
AstraZeneca saw its new cancer drugs drive its growth in Japan in the first half of 2019, with sales in the country rising 28% to US$1,173 million based on actual exchange rates. The company’s new oncology products fared strongly across...read more